SanBio Company Limited

Tokyo Stock Exchange 4592.T

SanBio Company Limited Operating Cash Flow for the year ending January 31, 2024: USD -32.51 M

SanBio Company Limited Operating Cash Flow is USD -32.51 M for the year ending January 31, 2024, a 43.09% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

SanBio Company Limited Operating Cash Flow for the year ending January 31, 2023 was USD -57.12 M, a -0.50% change year over year.
SanBio Company Limited Operating Cash Flow for the year ending January 31, 2022 was USD -56.84 M, a -14.15% change year over year.
SanBio Company Limited Operating Cash Flow for the year ending January 31, 2021 was USD -49.79 M, a 5.63% change year over year.
SanBio Company Limited Operating Cash Flow for the year ending January 31, 2020 was USD -52.76 M, a -44.76% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Tokyo Stock Exchange: 4592.T

SanBio Company Limited

CEO	Mr. Keita Mori MBA
IPO Date	April 8, 2015
Location	Japan
Headquarters	St. Luke Tower
Employees	29
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals Robotics

Description

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years